View Future GrowthRootK 過去の業績過去 基準チェック /06RootKの収益は年間平均-19.3%の割合で減少していますが、 Machinery業界の収益は年間 増加しています。収益は年間18.3% 2.5%割合で 減少しています。主要情報-19.31%収益成長率-16.57%EPS成長率Machinery 業界の成長18.85%収益成長率-2.49%株主資本利益率-76.62%ネット・マージン-140.89%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.すべての更新を表示Recent updatesBoard Change • Jul 30Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director JinMan Kwon was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.お知らせ • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).分析記事 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).分析記事 • Nov 05Abpro Bio Co., Ltd.'s (KOSDAQ:195990) 27% Price Boost Is Out Of Tune With RevenuesAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders are no doubt pleased to see that the share price has bounced 27% in...New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩69.2b market cap, or US$47.9m).分析記事 • Nov 03Would Abpro Bio (KOSDAQ:195990) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Aug 18Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 27%KOSDAQ:A195990 1 Year Share Price vs Fair Value Explore Abpro Bio's Fair Values from the Community and select yours The...分析記事 • Jul 25Abpro Bio (KOSDAQ:195990) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risk Market cap is less than US$100m (₩85.7b market cap, or US$62.4m).New Risk • Mar 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩22b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩22b). Market cap is less than US$100m (₩88.0b market cap, or US$60.0m).お知らせ • Mar 19Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 70, techno sunhwan-ro 1-gil, yuga-eup, dalseong-gun, daegu South Korea分析記事 • Mar 12Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Share Price Could Signal Some RiskAbpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...New Risk • Dec 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.分析記事 • Dec 06Abpro Bio Co., Ltd. (KOSDAQ:195990) Shares May Have Slumped 29% But Getting In Cheap Is Still UnlikelyAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders won't be pleased to see that the share price has had a very rough...New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩138.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Market cap is less than US$100m (₩138.1b market cap, or US$98.6m).分析記事 • Oct 21We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Aug 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩9.7b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩126.7b market cap, or US$94.9m).分析記事 • Jul 12Getting In Cheap On Abpro Bio Co., Ltd. (KOSDAQ:195990) Is UnlikelyWhen close to half the companies in the Machinery industry in Korea have price-to-sales ratios (or "P/S") below 1x, you...New Risk • Jun 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩136.1b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩136.1b market cap, or US$97.8m).お知らせ • Jun 18Abpro Bio Co., Ltd. announced that it has received KRW 6 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On June 17, 2024, Abpro Bio Co., Ltd. closed the transaction.New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (₩137.8b market cap, or US$99.6m).分析記事 • Mar 14Revenues Not Telling The Story For Abpro Bio Co., Ltd. (KOSDAQ:195990)Abpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 6.4x may look like a poor investment...New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.6b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (₩130.6b market cap, or US$98.9m).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 28Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion.Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion on September 26, 2022. As per the terms, the offer per share is KRW 3348 per share. Total number of shares acquired are 11,049,646. Transaction is expected to be closed on November 8, 2022.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.お知らせ • Jun 17Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment ArmAbpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for the gross proceeds of KRW 15,000,000,000 on June 16, 2021. The transaction will include participation from Meritz Securities Co., Ltd., Investment Arm. The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of June 18, 2024. The bonds can be 100% converted into 11,244,377 common shares of the company at a fixed conversion price of KRW 1,334 per share, representing the stake of 4.47% in the company. The conversion period start date is June 19, 2022 and end date is June 12, 2024. The subscription date is June 16, 2021. The payment date is June 18, 2021. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.分析記事 • Apr 05Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 17New 90-day low: ₩1,055The company is down 58% from its price of ₩2,515 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.分析記事 • Feb 02Abpro Bio (KOSDAQ:195990) Shareholders Booked A 92% Gain In The Last YearAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders might be concerned after seeing the share price drop 27% in the last...Is New 90 Day High Low • Nov 17New 90-day high: ₩1,490The company is up 110% from its price of ₩710 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 13% over the same period.Is New 90 Day High Low • Nov 02New 90-day high: ₩834The company is up 5.0% from its price of ₩797 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is down 3.0% over the same period.収支内訳RootK の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A195990 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2630,937-43,5859,86842831 Dec 2531,923-48,92010,96543730 Sep 2536,183-70,0297,17639530 Jun 2541,588-61,3406,86035031 Mar 2534,429-18,1687,08440531 Dec 2431,663-15,6295,50144830 Sep 2427,416-6,89210,28150030 Jun 2418,585-20,16210,38357331 Mar 2423,327-22,4529,33255731 Dec 2325,375-25,7429,83257330 Sep 2325,836-16,07410,76667430 Jun 2325,873-11,93311,16666031 Mar 2324,851-10,47511,61676731 Dec 2222,112-8,14511,11788030 Sep 2220,595-11,9378,27678830 Jun 2224,674-6,5907,77381231 Mar 2226,136-11,1698,96469231 Dec 2132,914-9,2557,78356230 Sep 2142,613-33,6318,11156330 Jun 2145,552-37,6167,18355331 Mar 2143,897-39,6675,38156331 Dec 2035,797-42,1106,04151930 Sep 2024,386-29,5747,6901,24030 Jun 2015,585-40,7428,2181,76831 Mar 2020,995-33,92511,1831,85731 Dec 1931,930-32,72412,4561,98530 Sep 1936,110-20,84210,2621,62730 Jun 1953,787-9,33711,46095331 Mar 1960,322-10,8119,38298731 Dec 1858,857-9,3908,6591,21330 Sep 1866,323-7,13611,58396430 Jun 1854,066-11,11811,73996431 Mar 1850,929-7,44911,81898031 Dec 1745,944-11,62612,0521,36930 Sep 1738,589-8,26711,3841,58530 Jun 1742,120-6,12511,6451,58531 Mar 1743,467-4,61511,1211,62931 Dec 1649,5211710,2691,54030 Sep 1653,1282,5818,0501,45330 Jun 1650,7683,7946,8161,45331 Mar 1664,1305,6017,4041,42631 Dec 1577,10115,0217,3701,49830 Sep 1595,49619,5678,7901,416質の高い収益: A195990は現在利益が出ていません。利益率の向上: A195990は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A195990は利益が出ておらず、過去 5 年間で損失は年間19.3%の割合で増加しています。成長の加速: A195990の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A195990は利益が出ていないため、過去 1 年間の収益成長をMachinery業界 ( 42.3% ) と比較することは困難です。株主資本利益率高いROE: A195990は現在利益が出ていないため、自己資本利益率 ( -76.62% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YCapital-goods 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/14 20:42終値2026/08/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋RootK Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
Board Change • Jul 30Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director JinMan Kwon was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.
お知らせ • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.
Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
分析記事 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...
New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).
分析記事 • Nov 05Abpro Bio Co., Ltd.'s (KOSDAQ:195990) 27% Price Boost Is Out Of Tune With RevenuesAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders are no doubt pleased to see that the share price has bounced 27% in...
New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩69.2b market cap, or US$47.9m).
分析記事 • Nov 03Would Abpro Bio (KOSDAQ:195990) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Aug 18Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 27%KOSDAQ:A195990 1 Year Share Price vs Fair Value Explore Abpro Bio's Fair Values from the Community and select yours The...
分析記事 • Jul 25Abpro Bio (KOSDAQ:195990) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risk Market cap is less than US$100m (₩85.7b market cap, or US$62.4m).
New Risk • Mar 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩22b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩22b). Market cap is less than US$100m (₩88.0b market cap, or US$60.0m).
お知らせ • Mar 19Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 70, techno sunhwan-ro 1-gil, yuga-eup, dalseong-gun, daegu South Korea
分析記事 • Mar 12Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Share Price Could Signal Some RiskAbpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...
New Risk • Dec 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
分析記事 • Dec 06Abpro Bio Co., Ltd. (KOSDAQ:195990) Shares May Have Slumped 29% But Getting In Cheap Is Still UnlikelyAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders won't be pleased to see that the share price has had a very rough...
New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩138.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Market cap is less than US$100m (₩138.1b market cap, or US$98.6m).
分析記事 • Oct 21We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Aug 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩9.7b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩126.7b market cap, or US$94.9m).
分析記事 • Jul 12Getting In Cheap On Abpro Bio Co., Ltd. (KOSDAQ:195990) Is UnlikelyWhen close to half the companies in the Machinery industry in Korea have price-to-sales ratios (or "P/S") below 1x, you...
New Risk • Jun 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩136.1b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩136.1b market cap, or US$97.8m).
お知らせ • Jun 18Abpro Bio Co., Ltd. announced that it has received KRW 6 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On June 17, 2024, Abpro Bio Co., Ltd. closed the transaction.
New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (₩137.8b market cap, or US$99.6m).
分析記事 • Mar 14Revenues Not Telling The Story For Abpro Bio Co., Ltd. (KOSDAQ:195990)Abpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 6.4x may look like a poor investment...
New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.6b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (₩130.6b market cap, or US$98.9m).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 28Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion.Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion on September 26, 2022. As per the terms, the offer per share is KRW 3348 per share. Total number of shares acquired are 11,049,646. Transaction is expected to be closed on November 8, 2022.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
お知らせ • Jun 17Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment ArmAbpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for the gross proceeds of KRW 15,000,000,000 on June 16, 2021. The transaction will include participation from Meritz Securities Co., Ltd., Investment Arm. The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of June 18, 2024. The bonds can be 100% converted into 11,244,377 common shares of the company at a fixed conversion price of KRW 1,334 per share, representing the stake of 4.47% in the company. The conversion period start date is June 19, 2022 and end date is June 12, 2024. The subscription date is June 16, 2021. The payment date is June 18, 2021. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.
分析記事 • Apr 05Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 17New 90-day low: ₩1,055The company is down 58% from its price of ₩2,515 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.
分析記事 • Feb 02Abpro Bio (KOSDAQ:195990) Shareholders Booked A 92% Gain In The Last YearAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders might be concerned after seeing the share price drop 27% in the last...
Is New 90 Day High Low • Nov 17New 90-day high: ₩1,490The company is up 110% from its price of ₩710 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 13% over the same period.
Is New 90 Day High Low • Nov 02New 90-day high: ₩834The company is up 5.0% from its price of ₩797 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is down 3.0% over the same period.